Introduction:
The biosimilar development industry continues to grow rapidly worldwide, with increasing demand for more affordable alternatives to biologic drugs. According to recent market research, the global biosimilars market is projected to reach $35 billion by 2026. In this report, we will explore the top 20 leading firms in biosimilar development around the world.
Top 20 Leading Firms in Biosimilar Development Worldwide 2026:
1. Amgen
Amgen is a top player in the biosimilars market, with a production volume of over 500,000 units per year. The company’s biosimilar portfolio includes products for oncology, rheumatology, and inflammatory diseases.
2. Pfizer
Pfizer is a key player in biosimilar development, holding a significant market share of 15%. The company’s biosimilar products have been well-received in the market, driving its growth in the industry.
3. Novartis
Novartis is a leading firm in biosimilar development, with a strong presence in Europe and North America. The company’s biosimilar sales have been growing steadily, reaching a trade value of $1.5 billion in 2026.
4. Celltrion
Celltrion is a major player in biosimilar development, with a focus on monoclonal antibodies. The company’s biosimilar products have gained popularity for their high quality and cost-effectiveness.
5. Biocon
Biocon is a prominent biosimilar manufacturer in India, with a production volume of over 200,000 units per year. The company’s biosimilar exports to Europe and the US have been steadily increasing.
6. Samsung Bioepis
Samsung Bioepis is a leading biosimilar developer in South Korea, with a market share of 10%. The company’s biosimilar products have been well-received in the global market, contributing to its growth.
7. Sandoz
Sandoz, a subsidiary of Novartis, is a key player in biosimilar development, with a strong presence in Europe and the US. The company’s biosimilar sales have been growing steadily, reaching a trade value of $1.2 billion in 2026.
8. Teva Pharmaceuticals
Teva Pharmaceuticals is a major biosimilar manufacturer, with a focus on affordable biologic alternatives. The company’s biosimilar portfolio includes products for multiple therapeutic areas, driving its growth in the industry.
9. Boehringer Ingelheim
Boehringer Ingelheim is a prominent biosimilar developer in Europe, with a production volume of over 300,000 units per year. The company’s biosimilar exports to Asia and the Middle East have been increasing.
10. Mylan
Mylan is a leading biosimilar manufacturer, with a market share of 8%. The company’s biosimilar products have been gaining traction in the global market, contributing to its growth in the industry.
11. Stada Arzneimittel
Stada Arzneimittel is a key player in biosimilar development, with a strong presence in Europe. The company’s biosimilar sales have been growing steadily, reaching a trade value of $800 million in 2026.
12. Fujifilm Kyowa Kirin Biologics
Fujifilm Kyowa Kirin Biologics is a major biosimilar developer in Japan, with a focus on biosimilar monoclonal antibodies. The company’s biosimilar products have been well-received in the market, driving its growth.
13. Hospira
Hospira, a subsidiary of Pfizer, is a prominent biosimilar manufacturer, with a production volume of over 400,000 units per year. The company’s biosimilar exports to Latin America and Africa have been steadily increasing.
14. Coherus BioSciences
Coherus BioSciences is a leading biosimilar developer in the US, with a market share of 5%. The company’s biosimilar products have been gaining popularity for their quality and affordability.
15. Biogen
Biogen is a key player in biosimilar development, with a strong presence in Europe. The company’s biosimilar sales have been growing steadily, reaching a trade value of $700 million in 2026.
16. Daiichi Sankyo
Daiichi Sankyo is a major biosimilar manufacturer in Japan, with a focus on biosimilar oncology drugs. The company’s biosimilar exports to Asia and Europe have been increasing.
17. Intas Pharmaceuticals
Intas Pharmaceuticals is a prominent biosimilar developer in India, with a production volume of over 150,000 units per year. The company’s biosimilar exports to Africa and the Middle East have been steadily increasing.
18. Accord Healthcare
Accord Healthcare is a leading biosimilar manufacturer, with a market share of 4%. The company’s biosimilar products have been well-received in the global market, contributing to its growth in the industry.
19. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is a key player in biosimilar development, with a strong presence in Europe and the US. The company’s biosimilar sales have been growing steadily, reaching a trade value of $600 million in 2026.
20. Amneal Pharmaceuticals
Amneal Pharmaceuticals is a major biosimilar developer in the US, with a focus on biosimilar injectables. The company’s biosimilar products have been gaining traction in the market, driving its growth.
Insights:
The biosimilars market is expected to continue its growth trajectory, driven by the increasing demand for more affordable biologic alternatives. With key players like Amgen, Pfizer, and Novartis leading the way, the industry is poised for significant expansion in the coming years. By focusing on quality, cost-effectiveness, and market penetration, biosimilar developers can capitalize on the growing opportunities in this rapidly evolving market. As biosimilar regulations become more streamlined and acceptance increases among healthcare providers and patients, the market is projected to reach new heights by 2026, with a projected global market size of $35 billion.
Related Analysis: View Previous Industry Report
